



## Vaccines for Respiratory Syncytial Virus

Guest Editors:

**Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, University of Georgia,  
Athens, GA 30602, USA

**Prof. Dr. Ultan F. Power**

Wellcome Wolfson Institute for  
Experimental Medicine, School of  
Medicine, Dentistry and  
Biomedical Sciences, Medical  
Biology Centre, 97 Lisburn Road,  
Belfast BT9 7BL, UK

Deadline for manuscript  
submissions:

**closed (31 May 2019)**

### Message from the Guest Editors

Dear Colleagues,

Respiratory syncytial virus (RSV) is the most common cause of serious acute lower respiratory illness in infants and young children, affecting nearly all children by the age of two years, as well as the elderly. Treatment is supportive as there is no licensed vaccine available. Improved understanding of the immunology and pathogenesis of RSV infection has led to the development of novel candidate vaccines. This Special Issue of *Vaccines* is directed toward reviewing basic and translational vaccines and disease intervention strategies for respiratory syncytial virus (RSV). This issue includes articles investigating the mechanisms of immunity and disease pathogenesis associated with RSV infection and RSV vaccines. A goal is to provide the reader with a better understanding of the conceptual and functional differences between innate and adaptive immune responses so as to provide the foundation for novel vaccines and antiviral approaches. This issue will also investigate the host and viral regulatory pathways involving regulation of immune responses RSV.

Prof. Dr. Ralph A. Tripp

Dr. Ultan F. Power

*Guest Editors*





an Open Access Journal by MDPI

## Editor-in-Chief

### **Prof. Dr. Ralph A. Tripp**

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

**Journal Rank:** JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)  
[X@Vaccines\\_MDPI](https://twitter.com/Vaccines_MDPI)